Thomas Sager
Chief Executive Officer
Thomas Sager has a Ph.D. in neuroscience and more that 24 years of drug discovery experience acquired in the biotech and pharma industry. For more than a decade he has held various leadership roles in R&D drug discovery at Lundbeck A/S, covering both neurology and psychiatry, and has taken through numerous projects from discovery to development. His scientific work generated over 35 peer-reviewed papers. Over the years he served as invited reviewer for many organizations, including the Michael J. Fox Foundation.
In 2012 Thomas Sager joined Business Development at Lundbeck A/S, where he served as Vice President, Head of Business Development, Licensing and Scientific Assessment until November 2020, and established the licensing strategy, was responsible for the execution of scientific assessments and was a project leader for corporate strategy initiatives. As part of his responsibilities in Business Development, Thomas Sager has been involved in multiple licensing, M&A opportunities and deals.
Kenneth V. Christensen
Chief Scientific Officer
Kenneth V. Christensen holds a Ph.D. in neuroscience and has more than two decades of drug discovery experience from the pharmaceutical industry. After receiving his Ph.D. degree from the University of Copenhagen, he began his pharma research career at Lundbeck A/S where he from 2004 to 2018 held various positions in the research organization. From 2009 to 2018 he worked as a Principal Scientist and Project Leader in the Department for Neurodegeneration focusing on developing disease-modifying treatment for patients suffering from neurological disorders such as Parkinson’s and Alzheimer’s disease. From 2018 to 2020 he served as Project Director and Research Program Director at Servier, France. Before joining Contera Pharma, he was responsible for the Neurology Research project portfolio at Servier as Research Program Director and Head of Neurology Research in the Immuno-inflammation & Neurology Therapeutic Area. Kenneth Christensen has published more than 25 scientific papers and book chapters, received funding from the Michael J. Fox Foundation, and actively participated in several large European Research Consortia.
Anders Brandt Elvang
Chief Business Officer – Head of Business Development
Anders Brandt Elvang holds a M.Sc. in human biology and a Ph.D. in neuroscience and has more than 15 years of broad pharma industry experience. He obtained his Ph.D. from the University of Copenhagen and Kings College London, and then joined Lundbeck A/S where he worked within Neuroscience Research, Department of Neurodegeneration from 2008 to 2013 as Senior Research Scientist. In 2013, Anders Brandt Elvang moved into Medical Affairs where he as Global Senior Medical Advisor supported Lundbeck´s late stage, mature neurology products within Alzheimer´s and Parkinson´s disease. From 2016 to 2020, Anders Brandt Elvang worked in Corporate Business Development & Strategy at Lundbeck A/S. Before joining Contera Pharma, he held the position of Senior Director, Business Development & Strategy, with focus on M&A, strategic partnerships, and corporate strategy projects.
Recent News
September 27, 2022
Vernalis Research, a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S announce a strategic collaboration in the field of RNA-targeting small molecules in neurology
Cambridge UK, and Copenhagen, Denmark, 27 September 2022 – Vernalis Research (“Vernalis”), a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S (“Contera”)…
Read more
September 08, 2022
Contera Pharma signs agreement with BDD Pharma for development of a novel tablet formulation to treat nocturnal symptoms and morning akinesia in Parkinson´s disease
Contera Pharma, a biotech company developing innovative therapies to treat neurological disorders, has entered into collaboration with BDD Pharma, a drug delivery…
Read more
Contact us
Contera Pharma Headquarter
Contera Pharma A/S
Venlighedsvej 4
2970 Hørsholm
Denmark
Thomas Sager, CEO
info@conterapharma.com
